Survival and tissue distribution of human t-cell clones in SCID mice

Rafat Abonour, Francine K. Cigel, Kathleen Schell, Christine S. Barnstable, Linda M. Sabatini, Vera Malkovska

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Evidence from animal experiments and clinical trials suggests that in vitro expanded T-cell clones could be useful in adoptive therapy of cancer and viral infections. To establish an in vivo model for adoptive therapy with cloned human T cells, we studied the survival and tissue distribution of human αβ CD4<sup>+</sup>T-cell clones transplanted intraperitoneally into mice with severe combined immune deficiency (SCID) mice. Four clones, expanded in vitro in recombinant human interleukin-2 (IL-2), were injected into 14 cyclophosphamide-conditioned mice, subsequently inoculated daily with IL-2. Using flow-cytometry analysis, human T cells were detected in the peritoneal cavity wash (PCW) but not in other tissues of 12 mice at 1 to 4 weeks after injection. A reverse transcriptase polymerase chain reaction (RT-PCR) specific for the constant region of human TCR β chain revealed a positive signal in 12 of 14 mice in PCW, eight in spleen, seven in lymph nodes, seven in liver, six in bone marrow, and two in blood. The frequency of human T-cell detection decreased with time. Five to seven sites were positive in mice killed at 1 week, one to four sites at 2 weeks, none to one site at 3 weeks, and three sites at four weeks. Thus human T-cell clones transplanted in SCID mice can survive for at least 4 weeks, even in the absence of specific antigen. The clones migrate at low levels outside the peritoneal cavity; therefore, the SCID mouse might serve as a model to study adoptive therapy with cloned T cells.

Original languageEnglish
Pages (from-to)10-18
Number of pages9
JournalJournal of Immunotherapy
Volume18
Issue number1
StatePublished - 1995
Externally publishedYes

Fingerprint

Severe Combined Immunodeficiency
Tissue Distribution
Clone Cells
Survival
T-Lymphocytes
Peritoneal Cavity
Interleukin-2
Virus Diseases
Reverse Transcriptase Polymerase Chain Reaction
Cyclophosphamide
Cell Survival
Flow Cytometry
Therapeutics
Spleen
Lymph Nodes
Bone Marrow
Clinical Trials
Antigens
Injections
Liver

Keywords

  • Immunotherapy
  • SCID mice
  • T-cell clones
  • Xenotransplantation

ASJC Scopus subject areas

  • Cancer Research
  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Abonour, R., Cigel, F. K., Schell, K., Barnstable, C. S., Sabatini, L. M., & Malkovska, V. (1995). Survival and tissue distribution of human t-cell clones in SCID mice. Journal of Immunotherapy, 18(1), 10-18.

Survival and tissue distribution of human t-cell clones in SCID mice. / Abonour, Rafat; Cigel, Francine K.; Schell, Kathleen; Barnstable, Christine S.; Sabatini, Linda M.; Malkovska, Vera.

In: Journal of Immunotherapy, Vol. 18, No. 1, 1995, p. 10-18.

Research output: Contribution to journalArticle

Abonour, R, Cigel, FK, Schell, K, Barnstable, CS, Sabatini, LM & Malkovska, V 1995, 'Survival and tissue distribution of human t-cell clones in SCID mice', Journal of Immunotherapy, vol. 18, no. 1, pp. 10-18.
Abonour R, Cigel FK, Schell K, Barnstable CS, Sabatini LM, Malkovska V. Survival and tissue distribution of human t-cell clones in SCID mice. Journal of Immunotherapy. 1995;18(1):10-18.
Abonour, Rafat ; Cigel, Francine K. ; Schell, Kathleen ; Barnstable, Christine S. ; Sabatini, Linda M. ; Malkovska, Vera. / Survival and tissue distribution of human t-cell clones in SCID mice. In: Journal of Immunotherapy. 1995 ; Vol. 18, No. 1. pp. 10-18.
@article{8e159e8292e84cb2abdcde48aa7af095,
title = "Survival and tissue distribution of human t-cell clones in SCID mice",
abstract = "Evidence from animal experiments and clinical trials suggests that in vitro expanded T-cell clones could be useful in adoptive therapy of cancer and viral infections. To establish an in vivo model for adoptive therapy with cloned human T cells, we studied the survival and tissue distribution of human αβ CD4+T-cell clones transplanted intraperitoneally into mice with severe combined immune deficiency (SCID) mice. Four clones, expanded in vitro in recombinant human interleukin-2 (IL-2), were injected into 14 cyclophosphamide-conditioned mice, subsequently inoculated daily with IL-2. Using flow-cytometry analysis, human T cells were detected in the peritoneal cavity wash (PCW) but not in other tissues of 12 mice at 1 to 4 weeks after injection. A reverse transcriptase polymerase chain reaction (RT-PCR) specific for the constant region of human TCR β chain revealed a positive signal in 12 of 14 mice in PCW, eight in spleen, seven in lymph nodes, seven in liver, six in bone marrow, and two in blood. The frequency of human T-cell detection decreased with time. Five to seven sites were positive in mice killed at 1 week, one to four sites at 2 weeks, none to one site at 3 weeks, and three sites at four weeks. Thus human T-cell clones transplanted in SCID mice can survive for at least 4 weeks, even in the absence of specific antigen. The clones migrate at low levels outside the peritoneal cavity; therefore, the SCID mouse might serve as a model to study adoptive therapy with cloned T cells.",
keywords = "Immunotherapy, SCID mice, T-cell clones, Xenotransplantation",
author = "Rafat Abonour and Cigel, {Francine K.} and Kathleen Schell and Barnstable, {Christine S.} and Sabatini, {Linda M.} and Vera Malkovska",
year = "1995",
language = "English",
volume = "18",
pages = "10--18",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Survival and tissue distribution of human t-cell clones in SCID mice

AU - Abonour, Rafat

AU - Cigel, Francine K.

AU - Schell, Kathleen

AU - Barnstable, Christine S.

AU - Sabatini, Linda M.

AU - Malkovska, Vera

PY - 1995

Y1 - 1995

N2 - Evidence from animal experiments and clinical trials suggests that in vitro expanded T-cell clones could be useful in adoptive therapy of cancer and viral infections. To establish an in vivo model for adoptive therapy with cloned human T cells, we studied the survival and tissue distribution of human αβ CD4+T-cell clones transplanted intraperitoneally into mice with severe combined immune deficiency (SCID) mice. Four clones, expanded in vitro in recombinant human interleukin-2 (IL-2), were injected into 14 cyclophosphamide-conditioned mice, subsequently inoculated daily with IL-2. Using flow-cytometry analysis, human T cells were detected in the peritoneal cavity wash (PCW) but not in other tissues of 12 mice at 1 to 4 weeks after injection. A reverse transcriptase polymerase chain reaction (RT-PCR) specific for the constant region of human TCR β chain revealed a positive signal in 12 of 14 mice in PCW, eight in spleen, seven in lymph nodes, seven in liver, six in bone marrow, and two in blood. The frequency of human T-cell detection decreased with time. Five to seven sites were positive in mice killed at 1 week, one to four sites at 2 weeks, none to one site at 3 weeks, and three sites at four weeks. Thus human T-cell clones transplanted in SCID mice can survive for at least 4 weeks, even in the absence of specific antigen. The clones migrate at low levels outside the peritoneal cavity; therefore, the SCID mouse might serve as a model to study adoptive therapy with cloned T cells.

AB - Evidence from animal experiments and clinical trials suggests that in vitro expanded T-cell clones could be useful in adoptive therapy of cancer and viral infections. To establish an in vivo model for adoptive therapy with cloned human T cells, we studied the survival and tissue distribution of human αβ CD4+T-cell clones transplanted intraperitoneally into mice with severe combined immune deficiency (SCID) mice. Four clones, expanded in vitro in recombinant human interleukin-2 (IL-2), were injected into 14 cyclophosphamide-conditioned mice, subsequently inoculated daily with IL-2. Using flow-cytometry analysis, human T cells were detected in the peritoneal cavity wash (PCW) but not in other tissues of 12 mice at 1 to 4 weeks after injection. A reverse transcriptase polymerase chain reaction (RT-PCR) specific for the constant region of human TCR β chain revealed a positive signal in 12 of 14 mice in PCW, eight in spleen, seven in lymph nodes, seven in liver, six in bone marrow, and two in blood. The frequency of human T-cell detection decreased with time. Five to seven sites were positive in mice killed at 1 week, one to four sites at 2 weeks, none to one site at 3 weeks, and three sites at four weeks. Thus human T-cell clones transplanted in SCID mice can survive for at least 4 weeks, even in the absence of specific antigen. The clones migrate at low levels outside the peritoneal cavity; therefore, the SCID mouse might serve as a model to study adoptive therapy with cloned T cells.

KW - Immunotherapy

KW - SCID mice

KW - T-cell clones

KW - Xenotransplantation

UR - http://www.scopus.com/inward/record.url?scp=0029083735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029083735&partnerID=8YFLogxK

M3 - Article

C2 - 8535566

AN - SCOPUS:0029083735

VL - 18

SP - 10

EP - 18

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 1

ER -